{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:15:01Z","timestamp":1780416901527,"version":"3.54.1"},"reference-count":53,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Heart failure (HF) with preserved ejection fraction (pEF) has lacked effective treatments for reducing mortality. However, previous studies have found an association between statin use and decreased mortality in patients with HFpEF. The aim of this study was to analyse whether statin therapy is associated with a reduction in mortality in these patients and whether the effect differs according to the presence or absence of ischaemic heart disease (IHD). Methods: We analysed data from the National Registry of Heart Failure, a prospective study that included patients admitted for HF in Internal Medicine units nationwide. Patients with HFpEF were classified according to the use of statins, and the differences between the two groups were analysed. A multivariable analysis was performed using Cox regression to assess factors independently related to mortality. Results: A total of 2788 patients with HFpEF were included; 63% of them were women with a mean age of 80.1 (\u00b17.8) years. The statin-treated group (40.2%) was younger, with better functional status, and had a more common diagnosis of vascular disease and lower frequency of atrial fibrillation. The most frequent aetiology of HF in both groups was the hypertensive one. Nevertheless, ischaemic HF was more common in those who received statins (24.8% vs. 9.6%; p &lt; 0.001). Multivariable analysis showed lower mortality at the 1-year follow-up in statin-treated patients (OR: 0.74; 95%CI: 0.61\u20130.89; p = 0.002). This association was observed in patients without IHD (p &lt; 0.001) but not in those with IHD (p = 0.11). Conclusions: Statins are associated with a decrease in total mortality in patients with HFpEF. This benefit occurs mainly in those without IHD.<\/jats:p>","DOI":"10.3390\/jcm13195844","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T07:19:37Z","timestamp":1727680777000},"page":"5844","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic Impact of Statins in Heart Failure with Preserved Ejection Fraction"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0380-3659","authenticated-orcid":false,"given":"Samanta","family":"Ortega-Hern\u00e1ndez","sequence":"first","affiliation":[{"name":"Internal Medicine Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35010 Las Palmas de Gran Canaria, Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6075-4945","authenticated-orcid":false,"given":"Sonia","family":"Gonz\u00e1lez-Sosa","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35010 Las Palmas de Gran Canaria, Las Palmas, Spain"},{"name":"Health Sciences Faculty, Universidad de Las Palmas de Gran Canaria, 35016 Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-3880","authenticated-orcid":false,"given":"Alicia","family":"Conde-Martel","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35010 Las Palmas de Gran Canaria, Las Palmas, Spain"},{"name":"Health Sciences Faculty, Universidad de Las Palmas de Gran Canaria, 35016 Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-3475","authenticated-orcid":false,"given":"Joan Carles","family":"Trull\u00e0s","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital d\u2019Olot i Comarcal de la Garrotxa, 17800 Girona, Spain"},{"name":"Tissue Repair and Regeneration Laboratory (TR2Lab), Institut de Recerca i Innovaci\u00f3 en Ci\u00e8ncies de la Vida i de la Salut a la Catalunya Central (IrisCC), Faculty of Medicine, University of Vic\u2014Central University of Catalonia (UVic-UCC), Ctra. de Roda, 70, 08500 Vic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0988-0599","authenticated-orcid":false,"given":"Pau","family":"Ll\u00e0cer","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), Universidad de Alcal\u00e1, 28801 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9340-5896","authenticated-orcid":false,"given":"Jos\u00e9","family":"P\u00e9rez-Silvestre","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Consorcio Hospital General Universitario de Valencia, 46014 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2654-9339","authenticated-orcid":false,"given":"Jos\u00e9 Carlos","family":"Ar\u00e9valo-Lorido","sequence":"additional","affiliation":[{"name":"FundeSalud, 06800 M\u00e9rida, Badajoz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Casado","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Universitario de Getafe, 28905 Madrid, Spain"},{"name":"Facultad de Ciencias Biom\u00e9dicas y de la Salud, Universidad Europea de Madrid, 28670 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3587-298X","authenticated-orcid":false,"given":"Francesc","family":"Formiga","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Universitario Bellvitge, 08907 L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Manzano","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), Universidad de Alcal\u00e1, 28801 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Lorenzo-Villalba","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, H\u00f4pitaux Universitaires de Strasbourg, 67000 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4294-1653","authenticated-orcid":false,"given":"Manuel","family":"Montero-P\u00e9rez-Barquero","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Universitario Reina Sof\u00eda, 14004 C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: A comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_2","first-page":"1","article-title":"Epidemiology of heart failure with preserved ejection fraction: Results from the RICA Registry","volume":"157","author":"Iborra","year":"2021","journal-title":"Med. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_4","first-page":"3627","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"Metra","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/ehf2.13805","article-title":"Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: A meta-analysis","volume":"9","author":"Pandey","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"ref_9","unstructured":"Solomon, S.D., McMurray, J.J., Vaduganathan, M., Claggett, B., Jhund, P.S., Desai, A.S., Henderson, A.D., Lam, C.S., Pitt, B., and Senni, M. (N. Engl. J. Med., 2024). Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction, N. Engl. J. Med., ahead of print."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","article-title":"Evaluation and management of heart failure with preserved ejection fraction","volume":"17","author":"Borlaug","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijcard.2016.03.186","article-title":"The effect of statins on mortality in heart failure with preserved ejection fraction: A meta-analysis of propensity score analyses","volume":"214","author":"Fukuta","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1253\/circj.CJ-14-0865","article-title":"Prognostic impact of statin use in patients with heart failure and preserved ejection fraction: A report from the chart-2 study","volume":"79","author":"Nochioka","year":"2015","journal-title":"Circ. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2143\/AC.63.6.2033384","article-title":"Statin therapy and mortality among patients hospitalized with heart failure and preserved left ventricular function\u2014A preliminary report","volume":"63","author":"Roik","year":"2008","journal-title":"Acta Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.cardfail.2005.10.014","article-title":"Statins associated with reduced mortality in patients admitted for congestive heart failure","volume":"12","author":"Folkeringa","year":"2006","journal-title":"J. Card. Fail."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archinte.165.1.62","article-title":"Statin use and survival outcomes in elderly patients with heart failure","volume":"165","author":"Ray","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1253\/circj.CJ-15-0016","article-title":"Statins beneficial for heart failure with preserved ejection fraction but not heart failure with reduced ejection fraction?","volume":"79","author":"Ohte","year":"2015","journal-title":"Circ. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2017.12.109","article-title":"Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease","volume":"255","author":"Tsujimoto","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2017.01.048","article-title":"Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study","volume":"232","author":"Kontogeorgos","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijcard.2015.01.063","article-title":"Predictors of two-year mortality in Asian patients with heart failure and preserved ejection fraction","volume":"183","author":"Yap","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1253\/circj.CJ-15-0514","article-title":"Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in japan\u2014Report from the CHART studies","volume":"79","author":"Ushigome","year":"2015","journal-title":"Circ. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1161\/CIRCHEARTFAILURE.115.002143","article-title":"Association between use of statins and mortality in patients with heart failure and ejection fraction of \u226550%","volume":"8","author":"Alehagen","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.amjcard.2013.12.023","article-title":"Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction","volume":"113","author":"Liu","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/clc.20615","article-title":"Statin therapy in patients with diastolic heart failure","volume":"33","author":"Tehrani","year":"2010","journal-title":"Clin. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjcard.2008.11.047","article-title":"Value of medical therapy in patients >80 years of age with heart failure and preserved ejection fraction","volume":"103","author":"Tehrani","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cardfail.2008.10.026","article-title":"Statin therapy and clinical outcomes in heart failure: A propensity-matched analysis","volume":"15","author":"Ouzounian","year":"2009","journal-title":"J. Card. Fail."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e007524","DOI":"10.1161\/JAHA.117.007524","article-title":"Prognostic impact of statin intensity in heart failure patients with ischemic heart disease: A report from the CHART-2 (Chronic Heart Failure Registry and Analysis in the Tohoku District 2) study","volume":"7","author":"Oikawa","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1253\/circj.CJ-18-0639","article-title":"Effect of statins on mortality in heart failure with preserved ejection fraction without coronary artery disease\u2015Report from the JASPER study","volume":"83","author":"Marume","year":"2019","journal-title":"Circ. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijcard.2022.12.006","article-title":"Systematic review and meta-analysis of the association between all-cause mortality and statin therapy in patients with preserved ejection fraction heart failure (HFpEF)","volume":"372","author":"Kaur","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12944-019-1135-z","article-title":"Association of statin use and clinical outcomes in heart failure patients: A systematic review and meta-analysis","volume":"18","author":"Anker","year":"2019","journal-title":"Lipids Health Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"GISSI-HF Investigators (2008). Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet, 372, 1231\u20131239.","DOI":"10.1016\/S0140-6736(08)61240-4"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_33","first-page":"61","article-title":"Functional evaluation: The barthel index","volume":"14","author":"Mahoney","year":"1965","journal-title":"Md. State Med. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1532-5415.1975.tb00927.x","article-title":"A Short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients","volume":"23","author":"Pfeiffer","year":"1975","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Heart Protection Study Collaborative Group (2003). MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 361, 2005\u20132016.","DOI":"10.1016\/S0140-6736(03)13636-7"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/2047487313480435","article-title":"Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: A network meta-analysis of placebo-controlled and active-comparator trials","volume":"20","author":"Naci","year":"2013","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jjcc.2013.03.013","article-title":"Clinical characteristics and long-term clinical outcomes of Japanese heart failure patients with preserved versus reduced left ventricular ejection fraction: A prospective cohort of Shinken Database 2004\u20132011","volume":"62","author":"Kaneko","year":"2013","journal-title":"J. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100869","DOI":"10.1016\/j.jacadv.2024.100869","article-title":"Initiation of Statins for Primary Prevention in Heart Failure With Preserved Ejection Fraction","volume":"3","author":"Orkaby","year":"2024","journal-title":"JACC Adv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ejhf.442","article-title":"Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: A systematic review","volume":"18","author":"Vaduganathan","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.amjcard.2018.04.027","article-title":"Comparison of effects of statin use on mortality in patients with heart failure and preserved versus reduced left ventricular ejection fraction","volume":"122","author":"Lee","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pharmthera.2013.09.001","article-title":"Statins in heart failure\u2014With preserved and reduced ejection fraction. An update","volume":"141","author":"Tousoulis","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1253\/circj.68.121","article-title":"Statins induce the regression of left ventricular mass in patients with angina","volume":"68","author":"Nishikawa","year":"2004","journal-title":"Circ. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1161\/01.CIR.0000034047.70205.97","article-title":"Hydroxymethylglutaryl coenzyme a reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21 ras activation","volume":"106","author":"Indolfi","year":"2002","journal-title":"Circulation"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijcard.2016.11.073","article-title":"Effects of statin therapy on arterial stiffness: A systematic review and meta-analysis of randomized controlled trial","volume":"227","author":"Upala","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0735-1097(01)01452-8","article-title":"Diastolic heart failure, diastolic left ventricular dysfunction and exercise intolerance","volume":"38","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.amjcard.2004.03.086","article-title":"Usefulness of statins in protecting against atrial fibrillation","volume":"94","author":"Abinader","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.cardfail.2005.06.439","article-title":"Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure","volume":"11","author":"Vrtovec","year":"2005","journal-title":"J. Card. Fail."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.clnu.2012.11.012","article-title":"Serum total cholesterol: A mortality predictor in elderly hospitalized patients","volume":"32","author":"Weiss","year":"2013","journal-title":"Clin. Nutr."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/07853890.2016.1197415","article-title":"Complex relationship of obesity and obesity paradox in heart failure\u2014higher risk of developing heart failure and better outcomes in established heart failure","volume":"48","author":"Alagiakrishnan","year":"2016","journal-title":"Ann. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/19\/5844\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:07:25Z","timestamp":1760112445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/19\/5844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":53,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["jcm13195844"],"URL":"https:\/\/doi.org\/10.3390\/jcm13195844","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]}}}